The Cooper Companies, Inc. (COO) Stock: Price, Forecast & Analyst Target
The Cooper Companies, Inc. (COO) — MoonshotScore 40/100 (Weak band), calculated Nov 18, 2026. Price $60.33 (-0.69%), as of the Nov 19, 2026 trading session; market cap $11.5B. Expected results Dec 3, 2026.
Listing-status flag — 8-K Item 3.01, filed Sep 12, 2023.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 74.34× (cash as of Jul 31, 2026) · expected results Dec 3, 2026
The Cooper Companies, Inc. · COO · NASDAQ · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: Cooper combines contact lenses with women’s and fertility health products, with CooperVision contributing the larger share of revenue. The case hinges on whether lens growth can regain momentum while CooperSurgical expands and cash generation carries a debt load far above cash.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · The Cooper Companies (COO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and elite growth. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Rising.
- EPS beat 7 of the last 8 reports
- expected results Dec 3, 2026
- Altman Z 3.00 · Piotroski F 7
Helping: business quality, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 40 | Weak | |
| 40 | Weak | |
| 40 | Weak | |
| 40 | Weak | |
| 40 | Weak | |
| 40 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $60.33 | |
| Change on the day | -0.69% | |
| 52-week range | $51.01–$89.83 | |
| Market capitalisation | $11.5B | — |
| Price / earnings (trailing) | 20.72 | |
| Shares traded on the day | 2.10M | |
| Beta (volatility vs the S&P 500) | 0.83 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Looking ahead, we expect MiSight growth to be in the low teens in Q4 against a difficult prior year comparison, resulting in roughly 20% growth for this full year and setting the stage for a promising 2027, supported by continued momentum in existing markets and the upcoming launch of MyDay MiSight toric.
Albert White · Statement from
For Q4, we expect consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%. We expect CooperVision revenue of $692 million to $706 million, down 2% to flat organically.
Brian Andrews · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for The Cooper Companies (COO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is The Cooper Companies (COO), and what does it report?
Short answer · as of
CooperVision sells spherical, toric, multifocal and specialty contact lenses for needs ranging from astigmatism and presbyopia to myopia and dry eyes.
Research dated 2026-09-13.
CooperSurgical serves women’s and family health through clinical devices, fertility consumables and services, genetic testing, diagnostics and contraception.
Consolidated revenue therefore blends lens purchases across global markets with demand from fertility clinics and other healthcare providers. CooperVision supplies the larger revenue base, so contact-lens performance has greater influence on the reported top line even though CooperSurgical broadens the business beyond vision correction.
What do the latest results show for The Cooper Companies (COO)?
Research dated 2026-09-13.
Revenue eased from the prior period, while operating profit and net income swung sharply positive after a loss. Revenue missed consensus even as the reported earnings measure exceeded expectations, so the profit rebound was materially stronger than the sales trend.
Management attributes near-term CooperVision weakness to channel inventory actions in the Americas and continued challenges in Asia Pacific, while describing Europe, the Middle East and Africa as resilient. Its outlook pairs muted vision performance with continued organic growth at CooperSurgical and sustained MiSight momentum despite a difficult comparison.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.07B Jul 31, 2026
- Latest quarter · R&D
- $41.60M Jul 31, 2026
- Latest quarter · SG&A
- $401.30M Jul 31, 2026
- Latest quarter · FMP standardized operating result
- $222.40M Jul 31, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 31, 2026 | $1.07B | $41.60M | $401.30M | $222.40M |
| Apr 30, 2026 | $1.08B | $42.50M | $676.20M | −$31.00M |
| Jan 31, 2026 | $1.02B | $44.30M | $390.20M | $212.80M |
| Oct 31, 2025 | $1.07B | $41.40M | $419.20M | $140.40M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.07B Sep 9, 2026
- Latest report · revenue estimate
- $1.10B Sep 9, 2026
- Latest report · revenue vs estimate
- Below estimate Sep 9, 2026
- Latest report · EPS vs estimate
- Above estimate Sep 9, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Sep 9, 2026 | $1.07B | $1.10B | $1.1500 | $1.1200 |
| Jun 4, 2026 | $1.08B | $1.05B | $1.2100 | $1.1000 |
| Mar 5, 2026 | $1.02B | $1.02B | $1.1000 | $1.0300 |
| Dec 4, 2025 | $1.07B | $1.06B | $1.1500 | $1.1100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jul 2025 | $1.06B | $98M | $0.49 (diluted) |
| Q4 FY2025 | $1.07B | $85M | $0.43 (diluted) |
| Q1 FY2026 | $1.02B | $131M | $0.66 (diluted) |
| Q2 FY2026 | $1.08B | -$78M | -$0.40 (diluted) |
What are the financial strengths and risks for The Cooper Companies (COO)?
Short answer
Cash and short-term investments were $154.70M at the Jul 31, 2026 balance-sheet date. Operating cash flow was $341.70M for the quarter ended Jul 31, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow has remained positive throughout the displayed history, and the cash balance has risen across recent periods. Current assets cover current liabilities, but quick assets do not; cash also remains small beside total debt, while the trailing free-cash-flow yield is thin.
Annual revenue has advanced, but net income has moved unevenly even as research and development spending climbed. A prolonged CooperVision slowdown would matter disproportionately because that segment supplies most revenue, and weaker cash conversion would leave less flexibility against the debt burden.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $341.70M Jul 31, 2026
- Previous quarter · operating cash flow
- $182.80M Apr 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jul 31, 2026 | $341.70M | −$68.70M |
| Apr 30, 2026 | $182.80M | −$86.40M |
| Jan 31, 2026 | $260.90M | −$102.20M |
| Oct 31, 2025 | $247.90M | −$98.00M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at The Cooper Companies (COO)?
Short answer · as of
The next earnings report is expected on Dec 3, 2026.
Research dated 2026-09-13.
Americas lens sales are the immediate operational tell. Stabilization would support management’s view that channel inventory actions are a near-term drag, while continued weakness would make that explanation less reassuring; the contrast between resilient European markets and challenged Asia Pacific markets deserves the same scrutiny.
MiSight growth and the MyDay MiSight toric rollout will show whether CooperVision can create product momentum despite softer regional demand. At CooperSurgical, sustained organic growth would demonstrate that the smaller business can offset some vision weakness.
Compare revenue with consensus alongside earnings at the scheduled report. Recent releases have repeatedly exceeded earnings expectations, but revenue has not cleared expectations consistently, making top-line delivery the cleaner confirmation of renewed operating momentum.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Within this, we expect regional performance trends to be broadly consistent with Q3, with the Americas reflecting the impact of channel inventory actions, EMEA delivering another solid quarter and Asia Pac continuing to face near-term challenges. We expect CooperSurgical revenue of $364 million to $374 million, representing organic growth of 4% to 6%.
Brian Andrews ·
Finally, while the strategic review process was extremely challenging for our teams, it provided valuable insights, and we believe we are well positioned to execute our plans and deliver strong performance in 2027 and beyond.
Albert White ·
How does The Cooper Companies compare with its peers?
Short answer
The Cooper Companies's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Relative to a business concentrated solely in contact lenses or fertility products, Cooper joins distinct demand engines under one company. Lens purchases depend on vision-correction demand, product mix and distributor ordering, while CooperSurgical participates in clinical procedures, fertility workflows, genetic testing and contraception.
Cooper is not simply a capital-equipment manufacturer: its offering spans lenses, consumables, devices and services. That breadth can produce different growth patterns within the same reporting period, although the larger CooperVision base keeps contact-lens execution more influential for consolidated results.
| Company | Price | Market value | Score |
|---|---|---|---|
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| $29.83 Nov 19, 2026 | $12.5B | 84 5-pillar Nov 18, 2026 | |
| $120.37 Nov 19, 2026 | $5.48B | 83 5-pillar Nov 18, 2026 | |
| $84.41 Nov 19, 2026 | $5.06B | 81 5-pillar Nov 18, 2026 | |
| $20.13 Nov 19, 2026 | $10.5B | 80 5-pillar Nov 18, 2026 | |
| $140.34 Nov 19, 2026 | $8.90B | 77 5-pillar Nov 18, 2026 | |
| $175.76 Nov 19, 2026 | $4.40B | 73 5-pillar Nov 18, 2026 | |
| $170.29 Nov 19, 2026 | $10.9B | 71 5-pillar Nov 18, 2026 | |
| $15.12 Nov 19, 2026 | $10.3B | 71 5-pillar Nov 18, 2026 | |
| $163.40 Nov 19, 2026 | $6.48B | 61 5-pillar Nov 18, 2026 | |
| $25.39 Nov 19, 2026 | $13.1B | 57 5-pillar Nov 18, 2026 | |
| The Cooper Companies (COO) — this page | $60.33 | $11.5B | 40 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $59.00 – $75.00
- Consensus target
- $65.11
- Median target
- $61.00
Consensus record · Captured .
Measured against a quoted price of $60.33 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 16, 2026
- Transactions
- 6
- Identified insiders
- 3
- Purchases
- 5
- Sales
- 0
- Other transactions
- 1
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 658 Period end Sep 30, 2026
- Previous quarter · holders
- 689 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 14,399,988 |
| Vanguard Capital Management LLC | 12,807,874 |
| State Street Corp | 8,860,902 |
| Vanguard Portfolio Management LLC | 8,276,738 |
| Browning West LP | 6,908,633 |
Tracked investors
Which of the 16 named investors we follow held COO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported COO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about The Cooper Companies (COO)?
The Cooper Companies Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why can CooperVision weaken even when patients still need contact lenses?
Management points to channel inventory actions in the Americas, so reported sales can reflect distributor ordering as well as patient demand. Regional performance also differs, with resilience in European markets alongside pressure in Asia Pacific.
How does CooperSurgical change the Cooper business mix?
CooperSurgical adds women’s health devices, fertility consumables and services, genetic testing, diagnostics and contraception to a company otherwise led by contact lenses. It is the smaller segment, but management expects it to grow while CooperVision faces near-term pressure.
What matters in the MyDay MiSight toric launch?
The rollout matters because it extends the MiSight franchise into toric lenses while management is seeking continued myopia-product momentum. Adoption would provide a product-specific counterweight to channel and regional pressure within CooperVision.
Why did Cooper’s latest profit rebound look stronger than its revenue trend?
Selling, general and administrative expense fell sharply from the prior period, coinciding with a return to operating profit even as revenue eased. The divergence makes expense discipline and the repeatability of the profit improvement important checks.
What is the COO stock price today?
The last price recorded for The Cooper Companies, Inc. (COO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the COO price target?
The analyst consensus price target for The Cooper Companies, Inc. (COO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 78 figures on this page — 3 from SEC filings and earnings calls, 67 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com